Gelhorn Heather, Garris Cindy, Arthurs Erin, Spinelli Frank, Cutts Katelyn, Chua Gin Nie, Collacott Hannah, Lebouché Bertrand, Lowman Erik, Rice Howard, Heidenreich Sebastian
Evidera, Bethesda, MD 20814, USA.
US Health Outcomes, ViiV Healthcare, Research Triangle Park, NC 27709, USA.
J Pers Med. 2022 Feb 23;12(3):334. doi: 10.3390/jpm12030334.
A long-acting injectable (LAI) antiretroviral therapy (ART) regimen is now available as a treatment option for virologically suppressed adults with HIV-1. This study assessed preference for a LAI regimen using an online survey of virally suppressed people living with HIV (PLWH) and physicians treating HIV in the US and Canada. Preference was elicited in a discrete choice experiment (DCE) with three choice options (switch to a LAI regimen, switch to another daily oral ART regimen, or stay on their current daily oral ART regimen) and four treatment attributes. A total of 553 PLWH and 450 physicians completed the survey. From the DCE results, 59% of PLWH were predicted to prefer a LAI over an alternative oral ART or staying on their current oral treatment, and 55-66% of physicians were predicted to recommend LAI for PLWH, depending on the treatment challenge scenario presented. PLWH indicated LAI would remove daily reminders of HIV (75%) and reduce feelings of being stigmatized (68%). A majority of PLWH and physicians preferred a LAI over oral ART to overcome treatment challenges such as daily pill burden and adherence. These benefits of LAI ART along with preferences of PLWH and physicians can help to inform ART choice.
长效注射用抗逆转录病毒疗法（LAI-ART）方案现已成为病毒学抑制的成人HIV-1感染者的一种治疗选择。本研究通过对美国和加拿大病毒学抑制的HIV感染者（PLWH）以及治疗HIV的医生进行在线调查，评估了对LAI方案的偏好。在一项离散选择实验（DCE）中引出偏好，该实验有三个选择选项（切换至LAI方案、切换至另一种每日口服抗逆转录病毒疗法方案或维持当前每日口服抗逆转录病毒疗法方案）以及四个治疗属性。共有553名PLWH和450名医生完成了调查。根据DCE结果，预计59%的PLWH会更倾向于LAI方案而非另一种口服抗逆转录病毒疗法方案或维持当前口服治疗方案，并且根据所呈现的治疗挑战场景，预计55%-66%的医生会为PLWH推荐LAI方案。PLWH表示LAI方案将消除每日对HIV的提醒（75%）并减少被污名化的感觉（68%）。大多数PLWH和医生更倾向于LAI方案而非口服抗逆转录病毒疗法方案，以克服诸如每日服药负担和依从性等治疗挑战。LAI-ART的这些益处以及PLWH和医生的偏好有助于为抗逆转录病毒疗法的选择提供参考。
